GlassScriptPhysician profile
Jennifer C Lee
NPI 1447409420
$9,676.97
in general payments reported to CMS, 2019-2025
48 companies · $1,924 in 2025
The $1,924 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $525 · 2021: $1,438 · 2022: $1,744 · 2023: $1,681 · 2024: $1,709 · 2025: $1,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,188 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,187.91 |
| Education | $126.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,496.42 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,324.74 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $964.50 | 2019-2025 | |
| Glaxosmithkline, LLC. | $837.95 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $769.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $535.01 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $427.32 | 2019-2023 | Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.51 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $315.20 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $288.51 | 2023-2025 | |
| Amgen INC. | $266.59 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $209.01 | 2019-2025 | Gardasil 9, Capvaxive, Vaqta |
| Sunovion Pharmaceuticals INC. | $160.65 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $139.22 | 2021-2025 | Zoryve, Livalo, Seglentis |
| Abbott Laboratories | $123.86 | 2021-2023 | Freestyle Libre 3 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.